Recent Updates
Recently added Catalysts

ADARx Pharmaceuticals, Inc.

ADRXFDA catalysts, PDUFA dates & pipeline intelligence
$14.2
▼ -0.71 · -4.76%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ADRX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
587.96 K
Value Traded
8.53 M
Short % Float
3.97%
Days to Cover
5.0
+2.9%Week
-19.46%1 Month

Cash Data

Unlock ADRX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.57 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
671.48 M
Total Shares
110.74 M
Float Shares
45.36 M
Insiders
59.08%
Institutions
4.83%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
onvuzosiran (PKK)
hereditary angioedema (HAE), prophylaxis to prevent attacks
Fast Track
Phase 3RNA-Based TherapiesRare Disease
Unlock every ADRX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ADRX Catalyst Timeline

Dated clinical, regulatory and corporate events for ADARx Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for ADARx Pharmaceuticals, Inc.

22Total events
8Upcoming
2Tier-1 (high impact)
2026 to 2030Coverage

Upcoming catalysts 2

T2R&D Day
Subscribe to view catalyst details
T2Timing Guidance
Subscribe to view catalyst details
onvuzosiran

Event history 12

●Quarterly UpdateCorporate
ADARx reported third quarter 2026 financial results
▲IpoCorporate
Closing of full exercise of underwriters' option for 3,937,500 additional shares in upsized IPO
▲Partnership / LicenseCorporate
AbbVie purchased 5,255,542 shares in concurrent private placement
▲Equity OfferingCorporate
AbbVie concurrent private placement of 5,255,542 shares at $17.00 per share
▲IpoCorporate
Expected closing of ADARx initial public offering
▲Equity OfferingCorporate
AbbVie concurrent private placement of ADARx common stock at $17.00 per share
▲IpoCorporate
ADARx common stock expected to begin trading on Nasdaq under ticker ADRX
●Stock ListingCorporate
ADARx common stock began trading on Nasdaq Global Select Market under ADRX
●IpoCorporate
IPO registration statements became effective with the SEC
▲IpoCorporate
ADARx closed IPO and concurrent private placement for ~$602.5 million gross proceeds
Unlock the full ADRX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ADRX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all ADRX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap
(rank 160 of 724)
Percentile Rank
Showing 7 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ADX-324 Small MoleculesNCT05691361Hereditary AngioedemaPhase 3 ACTIVE NOT_RECRUITING 233Dec 31, 2027
ADX-038 Small MoleculesNCT06989359IgANPhase 2 RECRUITING 45Jun 1, 2029
ADX-038 Small MoleculesNCT06990269Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 2 RECRUITING 240Aug 30, 2030
ADX-038 Small MoleculesNCT07522099Immunoglobulin A Nephropathy (IgAN)Phase 2 RECRUITING 30Jan 21, 2029
ADX-038 Small MoleculesNCT05876312Paroxysmal Nocturnal Hemoglobinuria (PNH)Phase 1/2 RECRUITING 50Jul 31, 2028
ADX-626 RNA-Based TherapiesNCT07081503UndisclosedPhase 1 RECRUITING 44Jun 30, 2027
ADX-850 Small MoleculesNCT06205628HypertensionPhase 1 ACTIVE NOT_RECRUITING 28Mar 31, 2027
Unlock the ADRX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ADRX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every ADRX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ADRX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
George SimeonDirector, 10% OwnerBuyOffering 592,593 592,593 held$17.00 09/28/2026
Unlock the full ADRX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ADRX for Q2 2026.
Unlock every fund holding ADRX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ADRX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ADRX ownership
Insider and institutional ownership, quarter by quarter.

ADRX Short Interest

Shares sold short, counted twice a month.

3.97%
Short % of Float
of tradable shares sold short
1.8M
Shares Sold Short
-5.4% vs prior count
5.0 High
Days to Cover
trading days of normal volume to buy every short share back
358.5K
Avg Daily Volume
the average used for days to cover
Unlock ADRX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ADRX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ADRX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ADRX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ADRX ranks across every disease it competes in

Competitive Position is a premium feature
See how ADRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ADRX News

-ADRX
Nov 12, 2026
ADRXGeneral
▼ -4.8%today

ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

ADARx Pharmaceuticals reported strong financial results for Q3 2026, highlighted by a successful IPO that raised approximately $602.5 million. The company is advancing three Phase 2 clinical trials for agazisiran and received Fast Track designation for onvuzosiran. With a cash position expected to last into 2030, ADARx is well-positioned for continued growth.

Read more →
-ADRX
Nov 9, 2026
ADRXConferences/Events

ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

ADARx Pharmaceuticals will have CEO Zhen Li participate in a fireside chat at the UBS Global Biopharma Conference on November 16, 2026. The event will be held in London and will include a live webcast. ADARx focuses on developing siRNA therapeutics for various diseases, with several programs in clinical stages.

Read more →
-ADRX
Oct 1, 2026
ADRXGeneral
▼ -6.6%on this news

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals announced the full exercise of underwriters' option to purchase an additional 3,937,500 shares in its IPO, raising total gross proceeds to approximately $513.2 million. The offering closed on October 1, 2026, with a total of 30,187,500 shares sold. Additionally, AbbVie purchased 5,255,542 shares in a concurrent private placement, bringing total proceeds to about $602.5 million.

Read more →
-ADRX
Sep 24, 2026
ADRXGeneral

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

ADARx Pharmaceuticals has announced the pricing of its upsized initial public offering, raising approximately $446.3 million by offering 26,250,000 shares at $17.00 each. The shares are expected to begin trading on Nasdaq on September 25, 2026, with a concurrent private placement involving AbbVie. The total gross proceeds from both offerings could reach around $535.2 million.

Read more →
-ADRX
Aug 24, 2026
ADRXFDA Updates

ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE

ADARx Pharmaceuticals has received FDA Fast Track designation for onvuzosiran, a siRNA therapeutic aimed at preventing hereditary angioedema (HAE) attacks. This designation is a significant milestone as it facilitates the drug's development and review process. Onvuzosiran is currently in Phase 3 trials and aims to offer improved control over HAE compared to existing treatments.

Read more →
-ADRX
Aug 12, 2026
ADRXGeneral

ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments

ADARx Pharmaceuticals has expanded its leadership team by appointing Ying Huang, Ph.D., to its Board of Directors and Robert Ackles as Chief People Officer. Dr. Huang's extensive experience in biotech and capital markets will support ADARx's growth strategy. Ackles brings nearly three decades of experience in building effective people strategies to enhance the company's culture and execution.

Read more →
-ADRX
Jun 8, 2026
ADRXPhases

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress

ADARx Pharmaceuticals will present Phase 1/2 data for onvuzosiran at the 2026 EAACI Congress. This investigational siRNA therapy targets hereditary angioedema (HAE) and aims to reduce plasma kallikrein levels. The ongoing Phase 3 STOP-HAE trial is designed to evaluate its efficacy in preventing HAE attacks.

Read more →
-ADRX
Mar 24, 2026
ADRXGeneral

ADARx Pharmaceuticals Expands Leadership Team with Appointment of Healthcare Investment Banking Veteran Ryan Fisk as Chief Financial Officer and Chief Business Officer

ADARx Pharmaceuticals appointed Ryan Fisk as Chief Financial Officer and Chief Business Officer. Fisk, with over 20 years of investment banking experience, will lead finance and corporate development. His background includes advising biotech companies on strategic transactions worth over $135 billion. ADARx focuses on RNA therapeutics across multiple therapeutic areas.

Read more →
-ADRX
Feb 27, 2026
ADRXPhases

ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE

ADARx Pharmaceuticals announced positive Phase 1/2 data for onvuzosiran, an investigational siRNA therapy for hereditary angioedema (HAE). The treatment demonstrated significant reductions in plasma kallikrein levels, with 80% reductions maintaining through Day 169. The ongoing Phase 3 STOP-HAE trial aims to further evaluate its efficacy and safety.

Read more →
-ADRX
Feb 20, 2026
ADRXConferences/Events

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

ADARx Pharmaceuticals announced it will present Phase 1/2 data and Phase 3 design for onvuzosiran (ADX-324) at the 2026 AAAAI Annual Meeting. This investigational siRNA therapy targets hereditary angioedema (HAE) by inhibiting prekallikrein. The presentation is scheduled for February 27, 2026, in Philadelphia, PA.

Read more →
-ADRX
Feb 5, 2026
ADRXGeneral

ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer

ADARx Pharmaceuticals appointed Dr. Donald Fong as Chief Medical Officer to lead its clinical development strategy. Dr. Fong has over 25 years of experience in clinical development across various therapeutic areas. His role will focus on advancing ADARx's ongoing Phase 2 and Phase 3 clinical trials and other programs.

Read more →
-ADRX
Dec 2, 2025
ADRXGeneral

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors

ADARx Pharmaceuticals appointed Dr. Mary Tagliaferri to its Board of Directors. With over three decades of experience in clinical development and regulatory strategy, she will enhance the company's leadership. Dr. Tagliaferri currently serves as Chief Medical Officer at Nektar Therapeutics and has a strong background in oncology and immunology.

Read more →

About ADARx Pharmaceuticals, Inc.

San Diego, CA adarx.com
Headquarters5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE
Trade the next ADRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime